Advertisement

Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide

  • Kota Yoshifuji
  • Takashi ToyaEmail author
  • Hiroto Adachi
  • Masahiro Fujita
  • Atsushi Wada
  • Ryosuke Konuma
  • Yuya Kishida
  • Tatsuya Konishi
  • Akihito Nagata
  • Yuta Yamada
  • Satoshi Kaito
  • Takuma Kumagai
  • Kyoko Inamoto
  • Megumi Akiyama
  • Aiko Igarashi
  • Yuho Najima
  • Noriko Doki
  • Takeshi Kobayashi
  • Kazuhiko Kakihana
  • Hisashi Sakamaki
  • Kazuteru Ohashi
Case Report
  • 41 Downloads

Abstract

Autologous stem-cell transplantation is an effective procedure for the treatment of multiple myeloma, and involves the collection of hematopoietic stem cells (HSCs). However, in some patients, HSCs in the bone marrow fail to mobilize. Pomalidomide upregulates CXCR4 in hematopoietic stem cells, in a manner similar to that of lenalidomide, and is, thus, likely to have a negative impact on hematopoietic stem-cell mobilization in multiple myeloma patients. Here, we report the two cases in which hematopoietic stem cells were mobilized using plerixafor plus granulocyte-colony stimulating factor after exposure to lenalidomide and pomalidomide. Use of plerixafor with a sufficient washout period may lead to successful mobilization following pomalidomide use, although further study of this potential use is needed.

Keywords

Pomalidomide Stem-cell mobilization Multiple myeloma Plerixafor CXCR4 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no competing financial interests to declare.

References

  1. 1.
    Attal M, Lauwers-Cances V, Hulin C, Lelu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.CrossRefGoogle Scholar
  2. 2.
    Sahin U, Demirer T. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. J Clin Apher. 2018;33:357–70.CrossRefGoogle Scholar
  3. 3.
    Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, et al. Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transpl. 2018;53:461–73.CrossRefGoogle Scholar
  4. 4.
    Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035–42.CrossRefGoogle Scholar
  5. 5.
    Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transpl. 2008;14:795–8.CrossRefGoogle Scholar
  6. 6.
    Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008;22:1282–4.CrossRefGoogle Scholar
  7. 7.
    Li S, Fu J, Ma H, Mapara MY, Lentzsch S. Lenalidomide-induced upregulation of CXCR7 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia. 2013;27:1407–11.CrossRefGoogle Scholar
  8. 8.
    Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075–85.CrossRefGoogle Scholar
  9. 9.
    San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015;100:1334–9.CrossRefGoogle Scholar
  10. 10.
    Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126:2284–90.CrossRefGoogle Scholar
  11. 11.
    Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127:2561–8.CrossRefGoogle Scholar
  12. 12.
    Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, et al. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. Int J Hematol. 2018;107:541–50.CrossRefGoogle Scholar
  13. 13.
    Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica. 2013;98:172–8.CrossRefGoogle Scholar
  14. 14.
    Domingues MJ, Nilsson SK, Cao B. New agents in HSC mobilization. Int J Hematol. 2017;105:141–52.CrossRefGoogle Scholar
  15. 15.
    Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867–74.CrossRefGoogle Scholar
  16. 16.
    Micallef IN, Ho AD, Klein LM, Marulkar S, Gandhi PJ, Calandra G, et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transpl. 2011;46:350–5.CrossRefGoogle Scholar
  17. 17.
    Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transpl. 2014;20:295–308.CrossRefGoogle Scholar
  18. 18.
    Sun Z, Zheng F, Wu S, Liu Y, Guo H, Liu Y. Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: a meta-analysis of phase III randomized controlled trials. Crit Rev Oncol Hematol. 2017;113:249–55.CrossRefGoogle Scholar
  19. 19.
    Sanchez-Ortega I, Querol S, Encuentra M, Ortega S, Serra A, Sanchez-Villegas JM, et al. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transpl. 2015;50:34–9.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Kota Yoshifuji
    • 1
  • Takashi Toya
    • 1
    Email author
  • Hiroto Adachi
    • 1
  • Masahiro Fujita
    • 1
  • Atsushi Wada
    • 1
  • Ryosuke Konuma
    • 1
  • Yuya Kishida
    • 1
  • Tatsuya Konishi
    • 1
  • Akihito Nagata
    • 1
  • Yuta Yamada
    • 1
  • Satoshi Kaito
    • 1
  • Takuma Kumagai
    • 1
  • Kyoko Inamoto
    • 1
  • Megumi Akiyama
    • 1
  • Aiko Igarashi
    • 1
  • Yuho Najima
    • 1
  • Noriko Doki
    • 1
  • Takeshi Kobayashi
    • 1
  • Kazuhiko Kakihana
    • 1
  • Hisashi Sakamaki
    • 1
  • Kazuteru Ohashi
    • 1
  1. 1.Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases CenterKomagome HospitalTokyoJapan

Personalised recommendations